We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medidata Solutions Clinical Cloud Gets Picked by Celgene
Read MoreHide Full Article
Headquartered in New York, Medidata Solutions Inc. recently announced that Celgene Corporation has adopted Medidata Clinical Cloud for using its suite of strategic monitoring tools and data analytics’ solutions.
Over the past one year, Medidata Solutions registered a return of almost 20.34%, which is higher than the Zacks categorized Medical Info Systems sub-industry’s gain of roughly 10.16%. The estimate revision trend also seems quite favorable for the stock at this moment, with one estimate moving up in the last 60 days and no downward movement, indicating chances of a recovery ahead. Notably, the current fiscal year estimate for the stock stands at 56 cents per share.
Further, we are optimistic about continued advancements in Medidata Solutions’ technology platforms, client base and sales pipeline. Also, a long-term expected earnings growth rate of 22.33% and a projected sales growth of 19.46% instill some confidence in its investors.
Medidata has been a gaining prominence lately with its broad-based product portfolio which includes Medidata Rave, Medidata Coder, Image Management, Risk-Based Monitoring, Medidata Balance, Medidata CTMS and Medidata Patient Cloud. Notably, Medidata Cloud addressed 800 life sciences companies in the last reported quarter and gave them an integrated platform to meet future development needs.
The company has been a pioneer in global drug development techniques, courtesy of its highly advanced cloud-based solutions for clinical research. Among the recent developments, the launch of AppConnect Partner Program is noteworthy. AppConnect combines Medidata’s cloud and mHealth technology with digital health firms to develop mobile apps related to health issues and remote patient research platforms.
Finally, the Cancer/Tumor Profiling market has bountiful prospects as it is forecast to reach a worth of $35 billion by 2018, growing at a CAGR of 18.5% (Markets And Markets). This highlights the prospects for Medidata’s Clinical Cloud platform in the market for cancer and tumor treatment in the coming quarters.
Glaukos has a long-term expected earnings growth rate of approximately 25%. Notably, the stock registered an impressive one-year return of 109.14%.
Penumbra has a long-term expected earnings growth rate of 20%. Notably, the stock witnessed a stellar one-year return of almost 32.9%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medidata Solutions Clinical Cloud Gets Picked by Celgene
Headquartered in New York, Medidata Solutions Inc. recently announced that Celgene Corporation has adopted Medidata Clinical Cloud for using its suite of strategic monitoring tools and data analytics’ solutions.
Over the past one year, Medidata Solutions registered a return of almost 20.34%, which is higher than the Zacks categorized Medical Info Systems sub-industry’s gain of roughly 10.16%. The estimate revision trend also seems quite favorable for the stock at this moment, with one estimate moving up in the last 60 days and no downward movement, indicating chances of a recovery ahead. Notably, the current fiscal year estimate for the stock stands at 56 cents per share.
Further, we are optimistic about continued advancements in Medidata Solutions’ technology platforms, client base and sales pipeline. Also, a long-term expected earnings growth rate of 22.33% and a projected sales growth of 19.46% instill some confidence in its investors.
Medidata has been a gaining prominence lately with its broad-based product portfolio which includes Medidata Rave, Medidata Coder, Image Management, Risk-Based Monitoring, Medidata Balance, Medidata CTMS and Medidata Patient Cloud. Notably, Medidata Cloud addressed 800 life sciences companies in the last reported quarter and gave them an integrated platform to meet future development needs.
The company has been a pioneer in global drug development techniques, courtesy of its highly advanced cloud-based solutions for clinical research. Among the recent developments, the launch of AppConnect Partner Program is noteworthy. AppConnect combines Medidata’s cloud and mHealth technology with digital health firms to develop mobile apps related to health issues and remote patient research platforms.
Finally, the Cancer/Tumor Profiling market has bountiful prospects as it is forecast to reach a worth of $35 billion by 2018, growing at a CAGR of 18.5% (Markets And Markets). This highlights the prospects for Medidata’s Clinical Cloud platform in the market for cancer and tumor treatment in the coming quarters.
Zacks Rank & Key Picks
Medidata has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Glaukos Corporation (GKOS - Free Report) , and Penumbra Inc. (PEN - Free Report) . Both companies sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos has a long-term expected earnings growth rate of approximately 25%. Notably, the stock registered an impressive one-year return of 109.14%.
Penumbra has a long-term expected earnings growth rate of 20%. Notably, the stock witnessed a stellar one-year return of almost 32.9%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>